Wellesta & Rubicon Research announce partnership to launch Nicotine Mini Lozenges in
Rubicon Research Pvt Ltd and Wellesta Holdings Pte. Ltd enter into a licensing and supply
partnership to launch a highly effective nicotine lozenge that helps smokers to quit smoking. This
smoking cessation product helps smokers successfully wean off their nicotine addiction in 12 weeks
and helps them embark on a healthier journey of living cigarette-free.
Wellesta Holdings Pte. Ltd is a Healthcare Company headquartered in Singapore and Rubicon
Research is an Intellectual Property led Pharmaceutical Company based out of India, the US and
Canada. This partnership will offer an effective smoking cessation product to our consumers in
The Nicotine Mini Lozenges are part of a 12-week therapy program, helping smokers gradually adjust
to having less nicotine till they no longer need any. The lozenges help relieve nicotine cravings and
alleviate withdrawal symptoms. The sugar-free lozenges are available in two strengths—2 mg and 4
mg—and come in a pack of 20 lozenges in 3 exciting flavors - Cherry, Cinnamon & Mint. Product will
be sold in Wellesta Brand name.
While talking about this unique product, Mr. Milan Paleja, Chairman and Managing Director of
Wellesta, said “With this collaboration we aim to help smokers quit the habit of Smoking and live
healthier life. We will launch this smoking cessation product in Singapore, Indonesia, Malaysia,
Philippines and Thailand and it will be sold under a Wellesta brand.”
Talking about the partnership, Parag Sancheti, Chief Executive Officer, Rubicon Research, said, “We
are excited to partner with Wellesta Holdings for the promotion and distribution of our products in
the Asia Pacific region. Finding the right partner who is aligned with our vision and core values is
important for us. Through this partnership we can leverage Wellesta’s powerful sales, marketing,
and distribution networks to provide an innovative product that helps people take charge of their
About Wellesta Holdings
Wellesta Holdings Pte Ltd is a healthcare company headquartered in Singapore with a direct market
presence in South-east Asia & India and partnering in MENA. We aim to serve clients and consumers
through commercial and marketing support using an innovative approach across the Wellesta value
chain. We work with companies to expand their presence in SEA & India as strategic partner for
companies present in these markets and acts as a representative for companies that are not present
in these markets and would like to sell/market their products in the region.
Wellesta Holdings operates in a spectrum of business verticals under our Partner Brands and Own
Brands, including Pharmaceutical, Nutraceuticals, OTC and Medical devices. Being led by industry-
proven leaders at HQ & country level. Wellesta works on extended arm for principals through win-
win partnership and provide superior quality products and services at right price, by working at full
compliance and transparency in business approach.
This joint venture supports the mission of Wellesta to provide cost-effective and high-quality
products and services and help to deliver better patient outcomes in healthcare.
About Rubicon Research Pvt Ltd
Rubicon Research is an IP led, specialty pharmaceutical company that develops, manufactures and
commercializes its value-added formulations for the global market. The company leverages its
proprietary technologies and specialized formulation development skills to provide solutions to
complex delivery challenges, enabling better patient outcomes.
Rubicon Research holds more than 50 issued patents in drug delivery technologies and its portfolio
spans multiple dosage forms, including oral solids, oral liquids, nasal, ophthalmic, injectable, sterile,
topical, drug device combinations, and fixed-dose combinations. Its flagship manufacturing facility
has been inspected by leading global health authorities, including the US FDA and UK MHRA.
Rubicon Research is a portfolio company of General Atlantic, a global growth equity investor with
nearly USD 35 billion in assets under management.
For additional information, please visit Rubicon